Pharmaceuticals
GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia
* Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV * Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy observed in adults with co-morbidities vii KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire...
2024-09-25 16:45
3730
Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies
* Belief BioMed and AskBio will work together to advance potential gene therapies in diseases with high unmet medical need, using a liver-targeted approach. SHANGHAI, Sept. 25, 2024 /PRNewswire/ -- Belief BioMed Inc. (BBM), a biotech company focusing on innovative gene therapies, today announce...
2024-09-25 14:58
6597
Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024
* Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports interchangeability between adalimumab and adalimumab-fkjp * Biosimilarity between Bmab 1200 and reference biologic-Ustekinumab in pivotal Phase 3 trial in patients with moder...
2024-09-25 13:21
2466
Amaran Biotech Makes Its Debut at BioJapan 2024 in Yokohama
HSINCHU, Sept. 25, 2024 /PRNewswire/ -- Amaran Biotech, a leading Taiwanes e CDMO (Contract Development & Manufacturing Organization) offering comprehensive pharmaceutical development and manufacturing solutions,will debut at BioJapan 2024 inYokohama from October 9-11. The company is participat...
2024-09-25 09:00
1471
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced thatJapan's Mini...
2024-09-24 15:30
4586
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
* XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. * XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug application (NDA) for XPOVIO ® in Indonesia with approval expected in the second half of 2024. ...
2024-09-23 17:42
5311
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia
* Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles inHong Kong and filed request for marketing authorization for Mainland China * Extension of Exclusive License and Distribution Agreement to include seven additional countries across East andS...
2024-09-23 15:00
7682
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
MELBOURNE, Australia, INDIANAPOLIS and LAKE MARY, Fla., Sept. 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET[1], SPECT[2] and th...
2024-09-23 07:38
3372
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
* HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - * HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 monoclonal antibody available inEurope for first-line treatment of ES- SCLC - * HANSIZHUANG (serplulimab) ha...
2024-09-21 13:42
6665
Cambrex Announces New Liquid-Phase Peptide Synthesis Manufacturing Technology
EAST RUTHERFORD, N.J., Sept. 19, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology that utilizes...
2024-09-19 18:00
4426
Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology
HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, tod...
2024-09-19 17:28
5291
Hyphens Pharma Launches Ceradan® Advanced Hand Balm, Specially Designed for Hand Eczema
SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Today, Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce the launch of Ceradan® A...
2024-09-19 14:00
3395
Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024
Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66). PRINCETON, N.J. and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), ...
2024-09-19 08:00
6615
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences
* Stockholders must vote by 11:59 p.m. ET on September 19, 2024 for their vote to count * A "FOR" vote on Proposals 3 & 5 by holders of a majority of the voting power of Kintara's outstanding shares as ofAugust 14, 2024 is required to allow for completion the proposed merger with TuHURA Biosc...
2024-09-18 20:30
5008
Epitomee Medical Announces FDA Clearance of its Capsule, Weight Management Device
Epitomee's Ingestible Capsule, Offers a Safe and Effective Prescription
Solution for Adults with BMI of 25-40 looking for Alternative Drug Free
Solutions for Their Weight Management Needs alongside diet and exercise.
CAESAREA, Israel, Sept. 17, 2024 /PRNewswire/ -- Epitomee Medical Ltd.
2024-09-18 09:00
3293
Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO Congress
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabol...
2024-09-18 08:00
4794
Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2024-09-18 08:00
4763
MedAdvisor Solutions Launches Pharmacy Advisory Group to Empower and Expand the Role of the Pharmacist
Industry leaders collaborate to bring innovative approaches to evolving pharmacy needs CAMBERWELL, Australia, Sept. 18, 2024 /PRNewswire/ -- MedAdvisor Solutions, a global leader in pharmacy-driven patient engagement solutions, announced today the launch of its Pharmacy Advisory Group. The colla...
2024-09-18 06:00
3245
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
MELBOURNE, Australia, Sept. 18, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET[1] ag...
2024-09-18 05:00
2684
Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity
- ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once-monthly subcutaneously and once-daily orally to treat obesity - ASC30 is two- to threefold more potent, in vitro, than orforglipron and stimulated significantly greater insulin secretion when comp...
2024-09-17 18:25
4617
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 263 media titles]
2026-10-05 11:51Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9345
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
8644
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8443
